Compare FRBT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBT | LXRX |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.0M | 996.7M |
| IPO Year | 2026 | 2000 |
| Metric | FRBT | LXRX |
|---|---|---|
| Price | $18.16 | $1.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $22.75 | $4.55 |
| AVG Volume (30 Days) | 105.6K | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $16.81 | $1.10 |
| 52 Week High | $22.00 | $2.68 |
| Indicator | FRBT | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 32.96 |
| Support Level | $18.11 | $1.50 |
| Resistance Level | $19.30 | $1.81 |
| Average True Range (ATR) | 0.84 | 0.12 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 57.45 | 7.54 |
Forbright Inc is a bank holding company. Along with its subsidiaries, it operates as a state chartered non-member bank, which serves the needs of individuals, small and medium sized businesses, and professional concerns. Its services include deposit and retail banking through a digital deposit platform, as well as financing and lending products such as lender finance loans, fund finance loans, healthcare finance loans, real estate loans, working capital facilities, warehouse lines of credit, and term loans.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.